Cyril Lenouen

Title: Cyril Lenouen: Innovator in Vaccine Development

Introduction

Cyril Lenouen is a notable inventor based in Bethesda, MD, who has made significant contributions to the field of vaccine development. With a focus on human respiratory syncytial virus (RSV), he has been instrumental in creating innovative vaccine candidates that exhibit attenuated phenotypes.

Latest Patents

Lenouen holds two patents related to vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes. His patents report presumptively de-attenuating mutations that are useful in producing recombinant strains of RSV exhibiting attenuation phenotypes. One of his notable constructs, Min_L-NPM2-1(N88K)L, demonstrates an attenuated phenotype, stability, and immunogenicity comparable to wild type RSV. The recombinant RSV strains described in his patents are suitable for use as live-attenuated RSV vaccines. Additionally, he provides polynucleotide sequences capable of encoding the described viruses, along with methods for their production and use.

Career Highlights

Cyril Lenouen has worked with prominent organizations such as Codagenix, Inc. and the National Institutes of Health, a component of the US Department of Health & Human Services. His work in these institutions has allowed him to advance his research and contribute to the development of effective vaccine solutions.

Collaborations

Lenouen has collaborated with esteemed colleagues, including Ursula J Buchholz and Peter L Collins, further enhancing the impact of his research in the field of vaccine development.

Conclusion

Cyril Lenouen's innovative work in developing vaccine candidates for RSV showcases his dedication to advancing public health through scientific research. His contributions are vital in the ongoing efforts to combat respiratory viruses and improve vaccine efficacy.